Valneva SE

VALNPhase 3

Valneva SE is a publicly traded biotech company dedicated to providing life-saving vaccines against infectious diseases. Its strategy combines commercial revenue from its travel and endemic vaccines with a late-stage pipeline targeting Lyme disease and other threats. The company leverages its proprietary vaccine platform technology and in-house manufacturing to control the entire value chain, positioning itself as a key player in the global response to emerging infectious diseases and neglected travel health markets.

Market Cap

$820.5M

Employees

700-800

Focus

Biotech

VALN · Stock Price

USD 9.4416.97 (-64.24%)

Historical price data

AI Company Overview

Technology Platform

Proprietary EB66® cell line for viral vaccine production and expertise in live-attenuated, inactivated whole-virus, and recombinant protein vaccine technologies.

Pipeline Snapshot

46 drugs in pipeline, 24 in Phase 3

Drug	Indication	Stage
IXIARO®	Japanese Encephalitis	Approved
IXIARO®- Japanese Encephalitis vaccine	Japanese Encephalitis Vaccine	Approved
IC51 + JE-VAX	Japanese Encephalitis	Phase 3
IC51 has given in the parent study IC51-322	Japanese Encephalitis	Phase 3
Japanese Encephalitis purified inactivated vaccine	Japanese Encephalitis	Phase 3

Funding History

Total raised: $210M

Debt$80MEuropean Investment BankMay 15, 2020

IPO$110MUndisclosedOct 3, 2013

Series A$20MBpifranceJun 15, 2013

Opportunities

Valneva has a first-mover advantage in the chikungunya vaccine market with IXCHIQ®, targeting both travelers and endemic populations.

The potential approval and launch of VLA15 for Lyme disease, in partnership with Pfizer, represents a blockbuster opportunity in North America and Europe.

The company's integrated manufacturing platform also provides opportunities for CDMO partnerships and rapid response to future pandemic threats.

Risk Factors

Key risks include clinical or regulatory failure of the late-stage Lyme disease candidate VLA15, which is critical to the company's valuation.

Commercial execution challenges in establishing the new chikungunya vaccine market and competing against future entrants pose significant hurdles.

The company also faces ongoing financial risk, requiring careful capital management to fund operations and commercialization while progressing its pipeline.

Competitive Landscape

Valneva competes in niche travel vaccine markets (e.g., against other Japanese encephalitis vaccines) and is pioneering the chikungunya vaccine market where it currently faces no direct competition but anticipates future candidates from Moderna and others. In Lyme disease, its VLA15 candidate is the most advanced, competing in a vacant market since the withdrawal of LYMErix. Its integrated model provides a key differentiation from many biotech peers.

Publications

Patents

Pipeline